Answer Genomics Profile
Key Indicators
- Authorised Capital ₹ 5.85 M
- Paid Up Capital ₹ 4.89 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 570.28%
- Profit Growth -149.05%
- Ebitda -57.48%
- Net Worth -91.58%
- Total Assets -58.33%
About Answer Genomics
Answer Genomics Private Limited (AGPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 13 December 2018 (Six years and one month 19 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.85 M and a paid-up capital of Rs 4.89 M, as per Ministry of Corporate Affairs (MCA) records.
Andiyakkal Balamurali and Rahul Ranganathan serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100KA2018PTC184492
-
Company No.
343041
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Dec 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Answer Genomics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Ranganathan
|
Director | 13-Dec-2018 | Current |
|
Andiyakkal Balamurali
|
Director | 11-May-2020 | Current |
Financial Performance of Answer Genomics.
Answer Genomics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 570.28% increase. The company also saw a substantial fall in profitability, with a 149.05% decrease in profit. The company's net worth observed a substantial decline by a decrease of 91.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Answer Genomics?
In 2023, Answer Genomics had a promoter holding of 78.88% and a public holding of 21.12%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nugenomics FoundationAndiyakkal Balamurali and Rahul Ranganathan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Answer Genomics?
Answer Genomics has a workforce of 3 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Answer Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Answer Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
